Singh S, Proudfoot JA, Dulai PS, et al. - Using patient-level data from phase 3 trials (ACT-1, ACT-2, and PURSUIT-SC), researchers compared the effectiveness and speed of onset of action of infliximab vs golimumab induction therapy in patients with moderate or severe ulcerative colitis (UC). They used the logistic generalized estimating equation to compare variations in proportions of individuals who achieved the composite outcome of a rectal bleeding score = 0 and stool frequency score ≤ 1 (patient-reported outcome 2 remission) at weeks 2 and 6 of treatment with standard-dose infliximab vs golimumab. Using logistic regression, overall effectiveness for inducing clinical remission (Mayo clinic score < 3) has been contrasted. Among the placebo groups in the studies, trial populations were comparable and no differences were noted. In patients with moderate-to-severe UC, infliximab resolves symptoms more rapidly and has greater efficacy for inducing remission compared with golimumab.